Trial · NCT04366739
Repurposing of Chlorpromazine in Covid-19 Treatment
NCT04366739, Phase 3, Withdrawn, Centre Hospitalier St Anne
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Repurposing of Chlorpromazine in Covid-19 Treatment. Trials, record NCT04366739. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04366739
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Repurposing of Chlorpromazine in Covid-19 Treatment
- NCT number
- NCT04366739
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Centre Hospitalier St Anne
- Conditions
- COVID-19
- Interventions
- CHLORPROMAZINE (CPZ), Standard of Care (SOC)
- First posted
- 2020-04-29
- Last updated
- 2024-07-10
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time To Response (TTR) | 28 days | The primary endpoint is the time to response (TTR) in days, from randomization to 28th day. By response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI) The WHO-OSCI is an ordinal scale of 9 severity levels (from 0 to 8) for COVID-19. This scale was established by the WHO, which recommends its use for any therapeutic study on COVID-19. This will be a continuous outcome defined by the amount of time between randomization to the first response. This will be treated as a time-to-event with possible censoring. |
| Secondary | Objective Response Rate (ORR) | 28 days from randomization | Response rate regarding the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI). This will be a binary outcome defined by clinical conditions improvement assessment from randomization to 28th Day, by the response to treatment is meant the reduction of at least one severity level on the World Health Organization Ordinal Scale for Clinical Improvement (WHO-OSCI). |
| Secondary | All-cause mortality | 28 days after randomization | All-cause mortality rates at Day 28th after randomization |
| Secondary | Duration in days required for hospital discharge | 28 days after randomization | This will be a continuous outcome defined by the amount of time in days between randomization and the hospital discharge |
| Secondary | Duration in days required for National Early Warning Score ≤ 2 maintained 24 hours | 28 days after randomization | This will be a continuous outcome defined by the amount of time in days between randomization and National Early Warning Score ≤ 2 maintained for almost 24 hours The National Early Warning Score (NEWS) is a score used in the ICU to evaluate the overall severity of the clinical condition of a patient. |
| Secondary | Number of days without oxygen therapy | 28 days after randomization | This will be a continuous outcome defined by the amount of time in days without oxygen therapy |
| Secondary | Incidence of oxygen use, NIV or high flow oxygen therapy | 28 days after randomization | Number of clinical conditions that need a prescription for Oxygen therapy, NIV or high flow oxygen therapy |
| Secondary | Duration in days of oxygen prescription, NIV or high flow oxygen therapy | 28 days after randomization | This will be a continuous outcome defined by the amount of time in days with oxygen therapy, NIV, or high flow oxygen therapy. |
| Secondary | Biochemical response: rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample | day 7 from randomization | Rate of patients positive for SARS-CoV-2 PCR on a nasopharyngeal sample (biobank sample) (day 7) This will be a binary outcome defined by positive or negative results at SARS-CoV-2 PCR on a nasopharyngeal sample |
| Secondary | Biochemical response: viral load of SARS-CoV-2 on a nasopharyngeal sample | day 7 from randomization | This will be a quantitative variable. Biobank sample at day 7 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04366739
GET https://conductscience.org/api/trials/v1/NCT04366739/registered?page=2